The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy and Safety of Long-Term Fluoxetine Versus Lithium Monotherapy of Bipolar II Disorder: A Randomized, Double-Blind, Placebo-Substitution Study
Open accessAbstract
OBJECTIVE: The authors examined the safety and efficacy of long-term fluoxetine monotherapy, lithium monotherapy, and placebo therapy in preventing relapse and recurrence of bipolar type II major depressive episode. The authors hypothesized that fluoxetine monotherapy would be superior to lithium monotherapy with a similar hypomanic mood conversion rate. METHOD: Patients at least 18 years old who recovered from their major depressive episode during initial open-label fluoxetine monotherapy were randomly assigned to receive 50 weeks of double-blind monotherapy with fluoxetine at 10-40 mg/day, lithium at 300-1200 mg/day, or placebo. The primary outcome measure was time to relapse or recurrence. Secondary outcome measures included the proportion of patients remaining well and the frequency of hypomanic symptoms. RESULTS: There were no significant differences in clinical or demographic characteristics among the fluoxetine (N=28), lithium (N=26), and placebo (N=27) groups. The mean time to relapse was 249.9 days for the fluoxetine group, 156.4 days for the lithium group, and 186.9 days for the placebo group. The hazard of relapse was significantly lower with fluoxetine compared with lithium, and the estimated hazard of relapse with lithium was 2.5 times greater than with fluoxetine. There were no statistically significant or clinically meaningful differences in hypomanic symptoms among treatment groups over time. One patient taking fluoxetine and one patient taking placebo discontinued treatment because of hypomania. CONCLUSIONS: These findings suggest that long-term fluoxetine monotherapy may provide superior relapse-prevention benefit relative to lithium monotherapy after recovery from bipolar II major depressive episode without an increase in hypomanic mood conversion episodes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a 50‐week RCT, the mean time to relapse into depression was significantly longer for fluoxetine than for lithium or placebo.”
From Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [469]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, head‐to‐head comparisons with antidepressants (reviewed below) found that lithium was not as effective in preventing depressive relapse as fluoxetine or venlafaxine.469, 497”
The cited source says what the claim attributes to it.
In the citing paper
“Hypomanic episodes occurred in a similarly low frequency in the three groups.469”
The cited source says what the claim attributes to it.
In the citing paper
“Patients had responded acutely to open‐label fluoxetine, making the sample enriched for fluoxetine response.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937
Crawley, M. J. (2005) · Wiley eBooks · doi:10.1002/9781119941750 · Cited by 894
Antidepressant-induced mania and cycle acceleration: a controversy revisited
Altshuler, L. L., Post, R. M., Leverich, G. S., Mikalauskas, K., ROSOFF, A. S., & Ackerman, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1130 · Cited by 607
Diagnosing Bipolar Disorder and the Effect of Antidepressants: A Naturalistic Study
Ghaemi, S. N., Boiman, E. E., & Goodwin, F. K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1013 · Cited by 501
Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T. M., McElroy, S. L., Keck, P. E., Kupka, R., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 420
Antidepressants in bipolar disorder: the case for caution
Ghaemi, S. N., Hsu, D. J., Soldani, F., & Goodwin, F. K. (2003) · Bipolar Disorders · doi:10.1046/j.1399-5618.2003.00074.x · Cited by 392
Antidepressant‐induced mania: an overview of current controversies
Goldberg, J. F., & Truman, C. J. (2003) · Bipolar Disorders · doi:10.1046/j.1399-5618.2003.00067.x · Cited by 312
Research works printed but not linked: 6
- Sachs GS , Printz DJ , Kahn DA , Carpenter D , Docherty JP : The Expert Consensus Guidelines: Medication Treatment of Bipolar Disorder, 2000: A Postgraduate Medicine Special Report. Columbus, Ohio, McGraw-Hill, 2000
- First MB , Spitzer RL , Gibbon M , Williams JBW : Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York, New York State Psychiatric Institute, Biometrics Research, 2001
- Goodwin FK , Jamison KR : Manic Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd ed. New York, Oxford University Press, 2007
- 10.4088/JCP.v62n1212 · DOI
- 10.1046/j.1399-5618.2003.00083.x · DOI
- 10.1016/j.jad.2006.01.024 · DOI
Cited by
Sorted by citations
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQUEEN, G. M., McIntyre, R. S., Sharma, V., et al. (2012) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,230
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“While some patients appear to benefit from carefully monitored use of antidepressants, others suffer iatrogenic mood destabilization due to induced elevated states (Amsterdam and Shults, 2010b; Sidor and MacQueen, 2011; Tondo et al., 2010b; Vázquez et al., 2011).”
BackgroundPacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Self-citationStuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 456
Metadata
- Authors
- Amsterdam, J. D., & Shults, J.
- Affiliations
- University of Pennsylvania (US)
- Venue
- American Journal of Psychiatry
- Published
- 2010-07-01
- Volume
- 167
- Issue
- 7
- Pages
- 792-800
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC2896440
- OpenAlex
- W1991845876
- Cited by
- 149
- References
- 38
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 7 · 2020: 10 · 2019: 11 · 2018: 11 · 2017: 8 · 2016: 10 · 2015: 5 · 2014: 9 · 2013: 16 · 2012: 20
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (MH 060353, R01MH080097, MH060998, R01MH060998, R01MH060353, MH077580, R34MH077580, MH080097)
- National Cancer Institute (R01CA096885)
- National Center for Complementary and Integrative Health (AT005074, R01AT005074)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar II disorder, fluoxetine, lithium, monotherapy, relapse prevention, major depressive episode, hypomania, long-term maintenance therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antidepressive Agents, Bipolar Disorder, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Time Factors, Lithium Compounds, Sample Size, Antidepressive Agents, Second-Generation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
